DETROIT – As doses of the Pfizer-BioNTech COVID-19 vaccine make their way into the arms of the first recipients, the data the Food and Drug Administration will be using to potentially authorize Moderna’s COVID-19 vaccine was made public. For the Moderna study, two doses of their mRNA vaccine were administered 28 days apart, that’s different than the 21 days between doses of the Pfizer vaccine. Twenty-five percent of those enrolled in the Moderna study were older than 65. That’s similar to the 21 percent in the Pfizer vaccine study who were in that age group. The primary question was how effectively the Moderna vaccine could prevent symptomatic COVID-19 infection 14 days after the second dose of the vaccine.